Tuesday, April 18 -  Welcome & Opening
09:00 - 14:00	Exhibition set-up
14:00 - 17:00	Opening of the registration desk
15:30 - 16:30	WELCOME RECEPTION

SESSION I - Natural Peptides To Drugs
16:30 - 16:45	Opening ceremony & Welcome notes
16:45 - 17:30	Opening Lecture:  Prof. Geoffrey W. TREGEAR Relaxin: the journey from discovery to clinical trials Howard Florey Institute, Australia
17:30 - 19:10	Oral presentations
	Prof. Robin Offord Using high technology to find simple solutions for developing countries The Mintaka Foundation for Medical Research
	Dr Maria Luisa Mangoni Short host-defence peptides from frog skin Università La Sapienza, Rome, Italy
	Dr David Deperthes Substrate peptides for the development of protease inhibitors Med Discovery SA, Geneva, Switzerland
	Prof. Sylvie Rebuffat Siderophore-microcins, antimicrobial peptides with potent activity against Enterobacteriaceae: structure, biosynthesis and recognition National Museum of Natural History, Paris, France
	Dr Reto Stöcklin Mass spectrometry mapping of Atheris snake venom reveals a new family of peptides Atheris Laboratories, Geneva, Switzerland
19:10 - 19:30	Hot-spot & lift presentations
	Dr Karine Puget New natural peptides for GPCR de-orphanization Genepep SA, Clapiers, France
	Dr Astrid Weiss Survivin – an inhibitor of apoptosis as a target for peptide based therapy of human breast cancer Georg Speyer Haus, Biomedical Research, Frankfurt am Main, Germany
	Dr Anne Fogli Peptidomics and proteomics studies of transformed lymphocytes from patients with leukodystrophy Atheris Laboratories, Geneva, Switzerland
	Prof. André Ménez "Venomics" or : The venomous systems genome project CEA-Saclay, France
20:15 -	SWISS-EVENT DINNER

Wednesday, April 19 -  From Natural Peptides
SESSION II - Genomics & Proteomics
8:15 - 9:00	Invited Lecture: Dr Michael J. BROWNSTEIN Venomics: A Primer J. Craig Venter Institute, Rockville, USA
9:00 - 10:00	Oral presentations
!!! NEW !!!	Dr Shubh Sharma From Peptides to Small Molecule Drug Candidates – Development of Melanotropin Receptor Ligands for the Treatment of Obesity Palatin Technologies, Inc., Cranbury, USA
	Mrs Anna Perchuc & Dr Laure Menin Structural and heparin-binding properties of two Bothrops moojeni phospholipases A2 and their derived C-terminal synthetic fragments Pentapharm Ltd., Basel & Atheris Laboratories, Geneva, Switzerland
	Prof. Ponnampalam Gopalakrishnakone Dual inhibitors of sPLA2 and MMP-1: A new potential therapeutic option for treatment of inflammation National University of Singapore, Faculty of Medicine, Singapore
10:00 - 10:30	COFFEE BREAK
SESSION III - Drug Discovery
10:30 - 11:15	Invited Lecture: Prof. Alan HARVEY Protease-activated receptors as targets for anti-inflammatory drug discovery Strathclyde Institute for Drug Research, UK
11:15 - 11:50	Hot-spot presentations
	Dr Inna Radzishevsky Structure-activity relationships in a novel class od antimicrobial pseudopeptides Technion, Haifa, Israel
	Prof. Paul Alewood Selenotoxins: A new chemical class of peptide drugs University of Queensland, Australia
	Dr Csaba Tömböly Design and synthesis of 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-one containing endomorphin-2 mimetics Institute of Biochemistry, Biological Research Center, Szeged, Hungary
	Dr Peter Cassidy The use of diastereomeric variation to produce peptide turn mimetics with low nanomolar affinity Mimetica Pty, Ltd, Brisbane, Australia
!!! NEW !!!	Prof. Alan Harvey The International Society on Toxinology 2006 World Congress in Glasgow Strathclyde Institute for Drug Research, UK
	Title and speaker to be advised
12:30 - 16:30	JOURNEY BY TRAIN TO GORNERGRAT MOUNTAIN (3'135 m) LUNCH BREAK OPEN AIR ACTIVITIES
SESSION IV - Lead identification
17:15 - 18:00	Invited Lecture: Dr Per Holse MYGIND Plectasin, beyond nature – improving the natural peptide and developing a process for bioproduction Novozymes A/S, Denmark
18:00 - 18:55	Oral presentations
	Prof. David Craik Structure and self association of the antiviral theta defensin retrocyclin-2 University of Queensland, Brisbane, Australia
	Dr Irmgard Irminger-Finger BARD1, a promising target for selective cancer cell killing University Hospitals Geneva HUG, Geneva Switzerland
	Dr Nicolas Gilles A GPCR binding toxin as a new drug candidate against lower urinary track symptoms CEA-Saclay, France
18:55 - 19:15	COFFEE BREAK
SESSION V - Lead optimisation
19:15 - 20:00	Invited Lecture: Dr Alain BECK Peptides as tools and drugs for immunotherapies Centre d'Immunlogie Pierre Fabre, Saint-Julien, France
20:00 - 20:40	Oral presentations
	Dr Jan Vrijbloed POL7001, a novel and potent pseudomonal antibiotic protects mice in a septicemia model Polyphor, Allschwil, Switzerland
	Dr Paul R. Hansen Identification of antibacterial lysine-peptoid hybrids using a mixture-based combinatorial library Royal Veterinary and Agricultural University, Copenhagen, Denmark
20:40 -	FREE EVENING

Thursday, April 20 - Through Development
SESSION VI - Drug design & Modelling
8:30 - 9:15	Invited Lecture: Dr John P. MAYER Melanocortin peptides for obesity Eli Lilly and Co., Indianapolis, USA
9:15 - 10:35	Oral presentations
	Dr Amram Mor Novel antimicrobial peptidomimetics composed of acylated charged amino acids Technion, Haifa, Israel
	Dr Emanuel Escher Molecular structures, ligand binding and activation mechanisms for peptidergic G-protein coupled receptors for rational drug design Faculté de Médecine et Sciences de la Santé, Sherbrooke, Canada
	Dr Marie Skovgaard Using evolutionary information to understand the structure-sequence relationship of GLP-1 agonists Novo Nordisk A/S, Maaloev, Denmark
	Prof. Anne Ulrich Structure and function of membrane-active peptides by solid state NMR University of Karlsruhe and Forschungszentrum Karlsruhe, Germany
10:35 - 11:00	COFFEE BREAK & POSTERS
SESSION VII - Production & Manufacturing
11:00 - 11:45	Invited Lecture: Prof. Stephen B. H. KENT Industrial chemical protein synthesis: what  will it take to make it happen? University of Chicago, USA
11:45 - 12:45	Oral presentations
	Dr Jon Nissen-Meyer Structure and mode of action of the membrane-permeabilizing antimicrobial peptide pheromone plataricin A University of Oslo, Norway
	Dr Luisa Bracci Protease-resistant branched peptides as tumor targeting agents University of Siena, Italy
	Prof. André Ménez The same small three-fingered fold for human uPAR and toxins CEA-Saclay, France
12:45 - 14:00	LUNCH BREAK
14:00 - 17:00	OPTIONAL ACTIVITIES & NETWORKING SESSIONS
SESSION VIII - Formulation & Drug Delivery
17:00 - 17:45	Invited Lecture: Dr Jennifer RIGGS-SAUTHIER The art of PEGylation: advancing peptide drugs into the future Nektar Therapeutics, Hunstville, USA
17:45 - 19:05	Oral presentations
	Dr Corina Borghouts-Heinz Peptides as inhibitors of signalling components in cancer cells Georg Speyer Haus, Biomedical Research, Frankfurt am Main, Germany
	Dr Michel Geffard Anti-bacterial activity of fatty acids linked on a polypeptide Laboratory PIOM-EPHE, Pessac, France
	Dr Jorg Ronco Evaluation of the E‑patch® technology for transcutaneous peptide delivery. MA320 model DBV Technologies, Boulogne Billancourt, France
	Prof. Keith Rose Multivalency – a way to enhance binding avidities and bioactivity – application to EPO Department of Structural Biology and Bioinformatics, University of Geneva, Switzerland
20:00 -	GALA DINNER

Friday, April 21 - To Clinics
SESSION IX - Development & Clinical Trials
8:30 - 9:15	Invited Lecture: Dr Patrick GARROUSTE Debio Group, Switzerland Key issues in the development of peptide drugs
9:15 - 10:35	Oral presentations
	Dr Chandra Panchal Evaluation of a prostate secretory protein94-derived synthetic peptide PCK3145 in patients with castrate metastatic prostate cancer: Inhibition of VEGF signaling, MMP-9 secretion and CD44-mediated MMP-9 cell surface binding Ambrilia Biopharma, Verdun, Quebec, Canada
	Dr Thomas Dix Non-natural arginine and lysine analogs in peptide drug development Argolyn Bioscience, Inc., North Charleston, USA
	Dr Markwin Velders Antimicrobial peptides; how good can they get ? AM-Pharma, Bunnik, Netherlands
	Prof. Paul Alewood Drug Discovery - where are we now and where are we going? University of Queensland, Australia
10:35 - 11:00	COFFEE BREAK
SESSION X - Route to Clinic
11:00 - 11:45	Closing Lecture: Dr George MILJANICH PRIALTÒ (ziconotide intrathecal infusion): a conopeptide for treating severe chronic pain Airmid LLC, USA
11:45 - 13:00	Roundtable: Peptides Drugs : Mistakes to Avoid ! Four presentations by experts in intellectual property, funding, production & regulatory. Followed by an open debate.
	Dr Emmanuel Jelsch Katzarov S.A., Switzerland
	Dr Peter Hoffmann Genzyme Pharmaceuticals, USA
	Dr Michel-Alain Mollard SPEF Venture, France
	Dr Daniel Bourgin Lonza, Switzerland
13:00 - 13:10	Closing Notes
13:10 -	FAREWELL COCKTAIL / LUNCHEON